Compare AbCellera Biologics Inc (ABCL) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Peloton Interactive Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Peloton Interactive Inc trades at $5.78 (market cap $2.52B). The key difference: AbCellera Biologics Inc and Peloton Interactive Inc are close in size by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | PTON | |
|---|---|---|
Market Cap | $2.35B | $2.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $9.00 |
52-Week Low | $2.78 | $3.71 |
Enterprise Value | $1.99B | $3.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Peloton (PTON) trades at $5.82, up 1.22% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals, with operating cash flow turning positive to $333 million in 2025 and net losses narrowing significantly. Recent news highlights a potential turnaround, including inclusion in the S&P SmallCap 600 index and the appointment of a new CFO.
The outlook is cautiously optimistic as Peloton aims for profitability, but risks remain from high debt and revenue declines. Analyst consensus is a Buy with a $7.50 price target, suggesting 29% upside, though execution on growth initiatives is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
